LIQUAEMIN SODIUM (heparin sodium) by Aspen Surgical is protein, antithrombin iii, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin ii, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly xa and iia. First approved in 1939.
Drug data last refreshed 19h ago · AI intelligence enriched 4w ago
LIQUAEMIN SODIUM (Heparin Sodium) is an injectable anticoagulant approved in 1939 that works by enhancing Antithrombin III activity to inhibit activated coagulation factors Xa and IIa, preventing blood clot formation. It is a protein-based therapeutic administered via injection used across multiple thrombotic indications. Heparin does not lyse existing clots but prevents their formation and stabilization.
As LOE approaches with moderate competitive pressure (30/100), commercial teams face declining market share and smaller team structures focused on defensive positioning.
protein, antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin II, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study With Heparin Sodium in Subcutaneous Administration
Study With Heparin Sodium in Intravenous Administration
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Worked on LIQUAEMIN SODIUM at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LIQUAEMIN SODIUM offers limited growth trajectory given its LOE status and minimal open job postings; roles focus on defending market share, managing generic competition, and operational excellence. Career advancement typically requires transition to growth-stage products or internal mobility within Aspen Surgical.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo